Format

Send to

Choose Destination
Nat Rev Neurol. 2017 Feb;13(2):96-104. doi: 10.1038/nrneurol.2016.182. Epub 2016 Dec 16.

Gene discovery in amyotrophic lateral sclerosis: implications for clinical management.

Author information

1
Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK.
2
UMC Utrecht Brain Center Rudolf Magnus, Universiteitsweg 100, 3584 CG, Utrecht, Netherlands.

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease predominantly affecting upper and lower motor neurons. The disease leads to relentlessly progressive weakness of voluntary muscles, with death typically resulting from diaphragmatic failure within 2-5 years. Since the discovery of mutations in SOD1, which account for ∼2% of ALS cases, increasing efforts have been made to understand the genetic component of ALS risk, with the expectation that this insight will not only aid diagnosis and classification, but also guide personalized treatment and reveal the mechanisms that cause motor neuron death. In this Review, we outline previous and current efforts to characterize genes that are associated with ALS, describe current knowledge about the genetic architecture of ALS - including the relevance of family history - and the probable nature of future gene discoveries, and explore how our understanding of ALS genetics affects present and future clinical decisions. We observe that many gene variants associated with ALS have effect sizes between those of mutations that greatly increase risk and those of common variants that have a small effect on risk, and combine this observation with insights from next-generation sequencing to explore the implications for genetic counselling.

PMID:
27982040
DOI:
10.1038/nrneurol.2016.182

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center